PDC*LINE PHARMA
PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens. PDC*line Pharma originated from a flagship R&D program of the French Blood Bank (EFS, Etablissement Franรงais du Sang) where PDC*line, a proprietary Plasmacytoid Dendritic Cell line (PDC) was developed from a patient with a PDC leukemia. Laurent LEVY President France & COO, and Joel PLUMAS, CSO founded the company in April 2014 in Grenoble and took the project to the clinical development stage with non-dilutive funding. Eric Halioua joined the team in February 2016, and became President and CEO in July 2016.
PDC*LINE PHARMA
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-04-01
Address:
La Tronche, Rhone-Alpes, France
Country:
France
Website Url:
http://www.pdc-line-pharma.com
Total Employee:
1+
Status:
Active
Contact:
+33 (0) 4 84 35 05 04
Email Addresses:
[email protected]
Total Funding:
41.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics Font Awesome Euro Google Maps
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Elstar Therapeutics
Fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating multi-functional therapeutics.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Employees Featured
Founder
Investors List
Hansongneotech
Hansongneotech investment in Series B - PDC*line Pharma
Alpha Holdings
Alpha Holdings investment in Series B - PDC*line Pharma
S.R.I.W.
S.R.I.W. investment in Series B - PDC*line Pharma
Korea Investment Partners
Korea Investment Partners investment in Series B - PDC*line Pharma
UTC Investment Co.
UTC Investment Co. investment in Series B - PDC*line Pharma
Brain Asset Management
Brain Asset Management investment in Series B - PDC*line Pharma
SFPI-FPIM
SFPI-FPIM investment in Series B - PDC*line Pharma
Sambrinvest
Sambrinvest investment in Series B - PDC*line Pharma
Meusinvest (Noshaq)
Meusinvest (Noshaq) investment in Series B - PDC*line Pharma
Shinhan-Cognitive Start-up Fund
Shinhan-Cognitive Start-up Fund investment in Series B - PDC*line Pharma
Official Site Inspections
http://www.pdc-line-pharma.com Semrush global rank: 9.33 M Semrush visits lastest month: 174
- Host name: cluster013.ovh.net
- IP address: 213.186.33.24
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris